Malignant hypertension

Summary

Malignant hypertension (MONDO:0006846) is a disease and 15 clinical trials. Top therapeutic interventions include labetalol and nifedipine. A subtype of hypertensive disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 15

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	malignant hypertension
Mondo ID	MONDO:0006846
EFO	EFO:1001031
MeSH	D006974
DOID	DOID:10824
SNOMED CT	70272006
UMLS	C0020540
MedGen	9374
MedDRA	10025600
Is cancer (heuristic)	no

Also known as: accelerated-malignant hypertension · hypertensive emergency · malignant phase hypertension · MHT

Disease family

This is a subtype of hypertensive disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › arterial disorder › hypertensive disorder › malignant hypertension

Related subtypes (11): essential hypertension, secondary hypertension, pulmonary hypertension, early onset hypertension, chemotherapy-induced hypertension, intracranial hypertension, ocular hypertension, kallikrein hypertension, hypertension, pregnancy-induced, resistant hypertension, hypertensive urgency

Subtypes (3): malignant hypertensive renal disease, malignant essential hypertension, malignant secondary hypertension

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Clevidipine	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 15.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	10
PHASE3	4
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05139238	PHASE4	TERMINATED	Postpartum Hypertension Study
NCT04670809	PHASE3	UNKNOWN	Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies
NCT05044364	PHASE3	UNKNOWN	Clinical Study of Clevidipine Butyrate Injection in the Treatment of Hypertensive Emergency and Sub-emergency
NCT05783557	PHASE3	UNKNOWN	A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency
NCT05922436	PHASE3	UNKNOWN	a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency
NCT03755726	Not specified	RECRUITING	A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort
NCT06286696	Not specified	NOT_YET_RECRUITING	Optic Nerve Sheath Diameter in Hypertensive Emergency
NCT06629363	Not specified	NOT_YET_RECRUITING	Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank
NCT00616616	Not specified	COMPLETED	Single Incision Laparoscopy
NCT02672787	Not specified	COMPLETED	A ED-based Intervention to Improve Antihypertensive Adherence
NCT02924805	Not specified	COMPLETED	Telemedical Versus Conventional Emergency Care of Hypertensive Emergencies
NCT04553653	Not specified	COMPLETED	Improving Acute Hypertension Management Through Emergency Department Checklist
NCT04991077	Not specified	COMPLETED	Interrupters of VAscular daMAge in Malignant Hypertension
NCT05155202	Not specified	UNKNOWN	Clinical Relevance of Nicardipine Induced Hypoxemia in the Intensive Care Unit
NCT06201572	Not specified	UNKNOWN	The Value of TOI in Evaluating Renal Function Damage in Hypertensive Emergency Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LABETALOL	4	1
NIFEDIPINE	4	1